Reset filter
Trefwoorden
Meer tonen Trefwoorden
Inhoudsopgave
  1. 1. Klinische studie
    1. 1.1. Opname/uitsluiting
    1. 1.2. Anamnese
    1. 1.3. Lichamelijk onderzoek
    1. 1.4. Score
    1. 1.5. Apparatieve diagnostiek
    1. 1.6. Laboratorium
    1. 1.7. Pathologie/Histologie
    1. 1.8. Voorlichting/akkoordverklaring
    1. 1.9. Therapie
    1. 1.10. Operatierapport
    1. 1.11. Ongewenst voorval
    1. 1.12. Follow-up
  2. 2. Routinedocumentatie
  3. 3. Register-/kohortstudies
  4. 4. Kwaliteitswaarborging
  5. 5. Datastandaard
  6. 6. Patiëntenvragenlijst
  7. 7. Medisch vakgebied
Geselecteerde datamodellen

U moet ingelogd zijn om meerdere datamodellen te selecteren en die te downloaden of te analyseren.

147 Zoekresultaten.
Relevantie Beoordeling Nieuwe eerst Oude eerst

Indirect Ophthalmoscopy Screening Ranibizumab Age-Related Macular Degeneration FVF3192g - Indirect Ophthalmoscopy Screening

- 22-02-18 - 1 Formulier, 4 Itemgroepen, 22 Data-elementen, 1 Taal
Itemgroepen: Indirect Ophthalmoscopy Right Eye, Indirect Ophthalmoscopy Left Eye , Retinal Break or Detachment right eye, Retinal Break or Detachment left eye
Study part: Indirect Ophthalmoscopy Screening. A Phase IIIb, Multicenter, Randomized, Double-Masked, Sham Injection-Controlled Study Of The Efficacy And Safety Of Ranibizumab In Subjects With Subfoveal Choroidal Neovascular (CNV) With Or Without Classic CNV Secondary To Age-Related Macular Degeneration.

Indirect Ophthalmoscopy Month 3 rhuFab V2 Neovascular Age-Related Macular Degeneration FVF2598g - Indirect Ophthalmoscopy Month 3

- 18-02-18 - 1 Formulier, 3 Itemgroepen, 11 Data-elementen, 1 Taal
Itemgroepen: Indirect Ophthalmoscopy Right Eye, Retinal Break or Detachment right eye, Retinal Break or Detachment left eye
Study part: Indirect Ophthalmoscopy Month 3. A Phase III, Multicenter, Randomized, Double-Masked, Sham Injection-Controlled Study Of The Efficacy And Safety Of rhuFab V2 (Ranibizumab) In Subjects With Minimally Classic Or Occult Subfoveal Neovascular Age-Related Macular Degeneration.

Indirect Ophthalmoscopy Day 0 rhuFab V2 Neovascular Age-Related Macular Degeneration FVF2598g - Indirect Ophthalmoscopy Day 0

- 18-02-18 - 1 Formulier, 3 Itemgroepen, 11 Data-elementen, 1 Taal
Itemgroepen: Indirect Ophthalmoscopy Right Eye, Retinal Break or Detachment right eye, Retinal Break or Detachment left eye
Study part: Indirect Ophthalmoscopy Day 0. A Phase III, Multicenter, Randomized, Double-Masked, Sham Injection-Controlled Study Of The Efficacy And Safety Of rhuFab V2 (Ranibizumab) In Subjects With Minimally Classic Or Occult Subfoveal Neovascular Age-Related Macular Degeneration.

Indirect Ophthalmoscopy Screening rhuFab V2 Neovascular Age-Related Macular Degeneration FVF2598g - Indirect Ophthalmoscopy Screening

- 18-02-18 - 1 Formulier, 4 Itemgroepen, 22 Data-elementen, 1 Taal
Itemgroepen: Indirect Ophthalmoscopy Right Eye, Indirect Ophthalmoscopy Left Eye , Retinal Break or Detachment right eye, Retinal Break or Detachment left eye
Study part: Indirect Ophthalmoscopy Screening. A Phase III, Multicenter, Randomized, Double-Masked, Sham Injection-Controlled Study Of The Efficacy And Safety Of rhuFab V2 (Ranibizumab) In Subjects With Minimally Classic Or Occult Subfoveal Neovascular Age-Related Macular Degeneration.

Indirect Ophthalmoscopy Month 12 rhuFab V2 Neovascular Age-Related Macular Degeneration FVF2587g - Indirect Ophthalmoscopy Month 12

- 04-02-18 - 1 Formulier, 3 Itemgroepen, 11 Data-elementen, 1 Taal
Itemgroepen: Indirect Ophthalmoscopy Right Eye, Retinal Break or Detachment right eye, Retinal Break or Detachment left eye
Study part: Indirect Ophthalmoscopy Month 12. A Phase III, Multicenter, Randomized, Double-Masked, Active Treatment-Controlled Study Of The Efficacy And Safety Of rhuFab V2 (Ranibizumab) Compared With Verteporfin (Visudyne®) Photodynamic Therapy In Subjects With Predominantly Classic Subfoveal Neovascular Age-Related Macular Degeneration.

Intraocular Pressure Month 12 rhuFab V2 Neovascular Age-Related Macular Degeneration FVF2587g - Intraocular Pressure Month 12

- 04-02-18 - 1 Formulier, 2 Itemgroepen, 15 Data-elementen, 1 Taal
Itemgroepen: Intraocular Pressure Pre- dose, Intraocular Pressure Post- dose
Study part: Intraocular Pressure Month 12. A Phase III, Multicenter, Randomized, Double-Masked, Active Treatment-Controlled Study Of The Efficacy And Safety Of rhuFab V2 (Ranibizumab) Compared With Verteporfin (Visudyne®) Photodynamic Therapy In Subjects With Predominantly Classic Subfoveal Neovascular Age-Related Macular Degeneration.

Baseline Visit (Day 1): EDSS evaluation BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS) (ENDORSE) NCT00835770

- 09-06-16 - 1 Formulier, 4 Itemgroepen, 15 Data-elementen, 1 Taal
Itemgroepen: Subject Identification, EDSS Evaluation, Functional System Scores, EDSS, Additional and Results
The primary objective of this study is to evaluate the long-term safety profile of BG00012 (dimethyl fumarate). Secondary objectives of this study are to evaluate the long-term efficacy of BG00012 using clinical endpoints and disability progression, to evaluate further the long-term effects of BG00012 on multiple sclerosis (MS) brain lesions on magnetic resonance imaging (MRI) scans in participants who had MRI scans as part of Studies 109MS301 (NCT00420212) and 109MS302 (NCT00451451) and to evaluate the long-term effects of BG00012 on health economics assessments and the visual function test. NCT00835770 Part: Baseline Visit (Day 1)

Molecular Monitoring Survey EUREKA - Case Report Form (CRF)

- 17-09-21 - 1 Formulier, 6 Itemgroepen, 27 Data-elementen, 1 Taal
Itemgroepen: Blood Sample Collection, Physician Information, Patient Information, CML Diagnosis, Treatment, Date & Signature, Addresses of reference laboratories
European survey on the assessment of deep molecular REsponse in chronic phase CML patients after at least two years of therapy with tyrosine KinAse inhibitors - major component of the Path to Cure Pillar of EUTOS III. ODM derived from: http://www.eutos.org/content/path_to_cure/eureka/index_eng.html

Slitlamp Examination Month 12 rhuFab V2 Neovascular Age-Related Macular Degeneration FVF2587g - Slitlamp Examination Month 12

- 04-02-18 - 1 Formulier, 3 Itemgroepen, 15 Data-elementen, 1 Taal
Itemgroepen: Slitlamp Examination, Findings of Inflammation right eye, Findings of Inflammation left eye
Study part: Slitlamp Examination Month 12. A Phase III, Multicenter, Randomized, Double-Masked, Active Treatment-Controlled Study Of The Efficacy And Safety Of rhuFab V2 (Ranibizumab) Compared With Verteporfin (Visudyne®) Photodynamic Therapy In Subjects With Predominantly Classic Subfoveal Neovascular Age-Related Macular Degeneration.

Baseline: Evoked Potentials Multiple Sclerosis ALAIN01 NCT02419378 - Baseline: Evoked Potentials Multiple Sclerosis ALAIN01 NCT02419378

- 03-06-16 - 1 Formulier, 1 Itemgroep, 33 Data-elementen, 1 Taal
Itemgroep: Evoked Potentials
Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential (ALAIN01) https://clinicaltrials.gov/ct2/show/NCT02419378 Principal Investigator Prof. Dr. Dr. Sven Meuth, University Hospital Muenster, Germany Part: Baseline

Month 24: Evoked Potentials Multiple Sclerosis ALAIN01 NCT02419378

- 03-06-16 - 1 Formulier, 1 Itemgroep, 33 Data-elementen, 1 Taal
Itemgroep: Evoked Potentials
Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential (ALAIN01) https://clinicaltrials.gov/ct2/show/NCT02419378 Principal Investigator Prof. Dr. Dr. Sven Meuth, University Hospital Muenster, Germany Part: Month 24

Month 36: Evoked Potentials Multiple Sclerosis ALAIN01 NCT02419378

- 03-06-16 - 1 Formulier, 1 Itemgroep, 33 Data-elementen, 1 Taal
Itemgroep: Evoked Potentials
Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential (ALAIN01) https://clinicaltrials.gov/ct2/show/NCT02419378 Principal Investigator Prof. Dr. Dr. Sven Meuth, University Hospital Muenster, Germany Part: Month 36

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial